- Home
- TGHL vs PASG Comparison
TGHL vs PASG Comparison
Compare TGHL & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | PASG |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | Singapore | United States |
| Employees | 7 | 27 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 15.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TGHL | PASG |
|---|---|---|
| Price | $1.15 | $4.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 7.5M | 36.6K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $3.29 |
| 52 Week High | $3.80 | $20.00 |
Technical Indicators
Market Signals| Indicator | TGHL | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 46.26 |
| Support Level | $0.37 | $4.25 |
| Resistance Level | $1.70 | $5.04 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 51.30 | 52.94 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates as the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, the company has developed a multi-faceted approach to address industry challenges. Its business currently comprises two main divisions, which are the Traceability and Authenticity Solutions and Carbon Project Development.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.